GlassScriptPhysician profile
Heather Harris
NPI 1578915765
$5,245.03
in general payments reported to CMS, 2019-2025
33 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $1,131 · 2023: $1,282 · 2024: $1,281 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $666.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $585.61 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Novo Nordisk INC | $544.40 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $456.88 | 2021-2025 | Farxiga, Airsupra |
| Abbvie INC. | $385.85 | 2021-2024 | |
| Amgen INC. | $278.19 | 2022-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.76 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.16 | 2022-2024 | |
| Pfizer INC. | $184.77 | 2022-2024 | |
| Gilead Sciences, INC. | $169.81 | 2025 | Yeztugo |
| Astellas Pharma US INC | $166.82 | 2021-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $146.12 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $138.81 | 2022-2024 | |
| Indivior INC. | $131.41 | 2021-2024 | Sublocade |
| Merck Sharp & Dohme LLC | $122.54 | 2021-2025 | Verquvo, Steglatro, Belsomra |
Show all 33 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.